Protagonist Therapeutics to Present Phase 1 Clinical and Preclinical Data on PTG-100 at UEG Week, Vienna

MILPITAS, Calif., Oct. 13, 2016

The global gastroenterology congress will be held in Vienna, Austria from October 15 - 19, 2016.

Poster Presentations: 

Poster Number P0298: Safety, Pharmacokinetics and Pharmacodynamics of the Novel Oral Peptide Therapeutic PTG-100 (alpha4-beta7 Integrin Antagonist) in Normal Healthy Volunteers
Date and time:	Monday October 17, 10:30 - 17:00, presentation 12:30 - 13:30 CET
Place:                       ARIVA.DE Börsen-Geflüster Kurse Protagonist Therapeutics 24,80 € -1,59%	Poster Exhibition -- Hall X4 and X5
Poster Session:	IBD I
Presenting author:	Richard S. Shames, MD, Protagonist Chief Medical Officer
Poster Number P0792: Pharmacokinetics and Pharmacodynamics Following Oral Administration of PTG-100, a Peptide Antagonist of Integrin alpha4-beta7
Date and time:	Tuesday October 18, 9:00 to 17:00, presentation 12:30 - 13:30 CET
Place:	Poster Exhibition -- Hall X4 and X5
Poster Session:	IBD II
Presenting author:	Thamilarasi Annamalai, M.S., Protagonist Senior Director, Preclinical Development

About Protagonist Therapeutics

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery, and potentially an opportunity for earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's initial lead product candidates, PTG-100 and PTG-200, are based on this approach, and the company believes they have the potential to transform the existing treatment paradigm for IBD, a GI disease consisting primarily of ulcerative colitis and Crohn's disease.

PTG-100, a potential first-in-class oral alpha-4-beta-7 integrin specific antagonist peptide product candidate that is being developed initially for moderate-to-severe ulcerative colitis, has now completed a phase 1 clinical trial in normal healthy volunteers.  PTG-200, a potential first-in-class oral Interleukin-23 receptor antagonist that is being developed initially for moderate-to-severe Crohn's disease, is currently in IND-enabling studies.

The company has a peptide technology platform that enables the discovery of oral and injectable peptides that can be utilized against a diverse set of targets and diseases including, but not confined to, GI targets and diseases. In addition to PTG-100 and PTG-200, the company is engaged in the discovery and development of injectable hepcidin mimetics, including one lead compound from this program, PTG-300, which is currently in pre-clinical development. These mimetics have potential utility for the treatment of iron overload disorders, such as transfusion dependent beta-thalassemia, hereditary hemochromatosis (HH) and sickle cell disease (SCD), each of which may qualify PTG-300 for orphan drug designation.  

Protagonist is headquartered in Milpitas, California with its pre-clinical and clinical staff in California, and discovery operations both in California and in Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.

Logo - http://photos.prnewswire.com/prnh/20130501/MM06086LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-phase-1-clinical-and-preclinical-data-on-ptg-100-at-ueg-week-vienna-300344780.html

SOURCE Protagonist Therapeutics, Inc.